The purpose of this study is to determine the ways in which androgen deprivation therapy for prostate cancer increases the risk of hypertension and cardiovascular diseases.
We are recruiting individuals with or without prostate cancer to participate in a research study to help us understand how androgen deprivation therapy affects cardiovascular health. Men with prostate cancer will be studied at the start and after 2 months of androgen deprivation therapy. Healthy men without prostate cancer will be studied before and after 2 months of sex hormone suppression or placebo. Main procedures include: Assessment of bone mineral density and body composition, ambulatory blood pressure monitoring, microneurography, glomerular filtration rate (iohexol clearance), renal plasma flow (paraminohippurate clearance)
1) Men aged 40 years or older 2) Healthy OR a recent prostate cancer diagnosis 3) No uncontrolled high blood pressure 4) Non-smoking 5) No use of hormone therapy currently or within the last year
Principal Investigator